Pentixapharm Holding AG (ETR:PTP)

Germany flag Germany · Delayed Price · Currency is EUR
2.090
+0.060 (2.96%)
Last updated: Apr 29, 2026, 9:02 AM CET
-27.05%
Market Cap 51.30M
Revenue (ttm) 526.00K
Net Income (ttm) -16.51M
Shares Out 24.78M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 4,258
Open 2.090
Previous Close 2.030
Day's Range 2.090 - 2.090
52-Week Range 1.300 - 3.700
Beta n/a
RSI 56.55
Earnings Date Mar 26, 2026

About Pentixapharm Holding AG

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 61
Stock Exchange Deutsche Börse Xetra
Ticker Symbol PTP
Full Company Profile

Financial Performance

In 2025, Pentixapharm Holding AG's revenue was 526,000, a decrease of -74.37% compared to the previous year's 2.05 million. Losses were -16.51 million, 26.4% more than in 2024.

Financial Statements

News

There is no news available yet.